Unknown

Dataset Information

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma.


ABSTRACT:

Objectives

There are no published reports for anti-interleukin-5 therapy in children <12 years with asthma. The primary objective of this study was to characterize the pharmacokinetics and pharmacodynamics of mepolizumab following subcutaneous (SC) administration in children 6 to 11 years-of-age with severe eosinophilic asthma.

Hypothesis

Mepolizumab SC pharmacokinetics and pharmacodynamics in children with severe eosinophilic asthma are comparable with adults.

Study design

Multinational, nonrandomised, open-label (NCT02377427).

Patient selection

Children 6 to 11 years-of-age with severe eosinophilic asthma (blood eosinophil count ≥150 cells/µL at screening or ≥300 cells/µL <12 months of screening) and ≥2 exacerbations in the prior year.

Methodology

Chil

SUBMITTER: Gupta A 

PROVIDER: S-EPMC6972599 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature